Later-Line Choices for Patients With Metastatic Breast Cancer

Trials Demonstrate First-Line Role of Sacituzumab in Metastatic TNBC

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

Selecting Cytotoxic Partner For Pembrolizumab in PD-L1+ TNBC

During a live event, Sara Nunnery, MD, MSCI, and participants discussed different chemotherapy agents that can be used with pembrolizumab in patients with metastatic triple-negative breast cancer.

Exploring Sacituzumab Survival, Dosing in Advanced Breast Cancer

During a live event, Megan Kruse, MD, discussed sacituzumab govitecan's benefit, dosing, toxicity, and an ongoing earlier-line trial in metastatic breast cancer.

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.

Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast cancer and the need for HER2-negative data with T-DXd.

Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple line of therapy.

Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy

During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.

Testing and Treatment Exposure Affect Options in Advanced Breast Cancer

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed biomarker testing and treatment exposure for a patient with metastatic breast cancer in the second article of a 2-part series.

Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.

UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.

Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.

Favorable Toxicity Management with Sacituzumab Govitecan in Advanced Breast Cancer

In the second article of a 2-part series, Aditya Bardia, MD, MPH, discusses the favorable toxicity profile of sacituzumab govitecan for patients with metastatic breast cancer and how he handles neutropenia through the course of treatment.

Survival Outcomes with Sacituzumab Govitecan Increase in HR+ mBC

In the first article of a 2-part series, Aditya Bardia, MD, MPH, explains how recent survival outcomes with sacituzumab govitecan impressed physicians treating patients with metastatic breast cancer.

Adjusting to Practice Changing ADCs in Advanced Breast Cancer

In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.

Considering the Sequence of ADCs in HR+, HER2- and HER2-Low Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth Mittendorf, MD, discussed how antibody-drug conjugates fit into the treatment algorithm for patients with advanced breast cancers.

Sacituzumab Govitecan Shows Efficacy in HR+, HER2- Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial of sacituzumab govitecan for patients with hormone receptor–positive, HER2-negative breast cancer.

Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC

Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC

Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Managing Sacituzumab AEs and Looking Forward to Next-Line TNBC Therapy

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.

Managing Adverse Events of Sacituzumab Govitecan in TNBC

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies

During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.

Selecting Frontline Therapy for TNBC After Progression on Adjuvant Therapy

During a Targeted Oncology case-based roundtable event, Elizabeth Ann Mittendorf, MD, discussed with participants their choice of treatment after progression for a patient with triple-negative breast cancer treated with adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel. This is the first of 2 articles based on this event.

Part 2: Managing Toxicities of Sacituzumab Govitecan in Metastatic TNBC

During a live virtual event, Rita Nanda, MD, discussed with participants how to address toxicities of sacituzumab govitecan and how to treat a patient who progresses after receiving this agent.

Part 1: Choosing Therapy for a Patient With Recurrent Metastatic TNBC

During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.

POLL: What Treatment Would You Choose for BRCA-, PD-L1- Metastatic TNBC?

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

POLL: What Treatment Would You Choose for BRCA-, PD-L1- Metastatic TNBC?

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

Part 2: Managing Sacituzumab-Associated Neutropenia in TNBC

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

Part 1: Sacituzumab Shows Efficacy in Second-Line Metastatic TNBC

During a live virtual event, Sara Tolaney, MD, discussed the results of the ASCENT trial of sacituzumab govitecan in patients with triple-negative breast cancer.

Part 2: Experiences With Sacituzumab and Biomarkers for TNBC

During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.

Part 1: Frontline Therapy Options for Rapid Recurrence in Metastatic TNBC

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.